Notice NOT-RM-18-006 from the NIH Guide for Grants and Contracts

Notice NOT-RM-18-005 from the NIH Guide for Grants and Contracts

Notice NOT-RM-18-003 from the NIH Guide for Grants and Contracts

Negotiable: Paramount Recruitment: Bioinformatician - Cancer - Barcelona Based in the beautiful city of Barcelona, a brand new opportunity has arisen for a talented Bioinformatician specialising in cancer to join one of the largest and most respected Bioinformatics consultancies in the wo Barcelona, Spain

Funding Opportunity RFA-MD-18-004 from the NIH Guide for Grants and Contracts. This initiative will support health services, intervention, and implementation research to understand and reduce racial/ethnic, geographic, and socioeconomic HIV disparities in US women. Projects may address HIV prevention, screening and diagnosis, and/or treatment. Projects may involve primary data collection and/or secondary analysis of existing data.

Funding Opportunity PAR-18-479 from the NIH Guide for Grants and Contracts. This initiative supports research to test the effectiveness of combined strategies to both detect and intervene to reduce the risk of suicide behavior, suicide ideation, and non-suicidal self-harm (NSSI) by youth in contact with the juvenile justice system. Opportunities for detection and prevention start at early points of contact (e.g., police interaction, the intake interview) and continue through many juvenile justice settings (e.g., pre-trial detention, juvenile or family court activities, court disposition, placement and on-going care in either residential or multiple community settings.) This FOA invites intervention strategies that are designed to be delivered in typical service settings using typically available personnel and resources, to enhance the implementation of interventions that prove effective, enhance their future uptake in diverse settings, and thereby reduce risk of suicide and self-harm in this population. This FOA is published in parallel to a companion R34 FOA (PAR-xx-xxx) supporting pilot studies in preparation for the larger-scale studies described here.

Notice NOT-TR-18-012 from the NIH Guide for Grants and Contracts

Notice NOT-HL-17-569 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-18-486 from the NIH Guide for Grants and Contracts. The purpose of the NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01) is to diversify the pool of independent neuroscience research investigators by providing junior faculty with research cost support, protected research time and career stage appropriate professional development mentorship in neuroscience research. Individuals from backgrounds underrepresented in biomedical research are eligible for support under this award if they have doctoral research degrees (Ph.D. or equivalent) and are in the first 3 years of a faculty tenure track or equivalent position at the time of award.

Funding Opportunity PAR-18-490 from the NIH Guide for Grants and Contracts. The purpose of the NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01) is to diversify the pool of independent neuroscience research investigators by providing junior faculty with research cost support, protected research time and career stage appropriate professional development mentorship in neuroscience research. Individuals from backgrounds underrepresented in biomedical research are eligible for support under this award if they have doctoral research degrees (Ph.D. or equivalent) and are in the first 3 years of a faculty tenure track or equivalent position at the time of award.

Interested candidates should submit their resume to hr@lucigen.com with Job #017270W in the subject line. Experience with biostatistics and computational data...
From Lucigen - Thu, 07 Dec 2017 11:47:36 GMT - View all Madison, WI jobs

Competitive paid internship: Illumina: This internship will allow a student with bioinformatics skills to apply their expertise in perfecting the current methods for mutational analysis. Great Chesterford, Saffron Walden

Notice NOT-RM-18-010 from the NIH Guide for Grants and Contracts

Notice NOT-RM-18-009 from the NIH Guide for Grants and Contracts

Notice NOT-HL-17-568 from the NIH Guide for Grants and Contracts

Notice NOT-OD-18-111 from the NIH Guide for Grants and Contracts

Notice NOT-DA-17-063 from the NIH Guide for Grants and Contracts

Notice NOT-OD-18-113 from the NIH Guide for Grants and Contracts

Notice NOT-HL-17-559 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-18-427 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage cooperative agreement applications to support early stage clinical trials of novel mechanism of action, investigational drugs or drug candidates for the treatment of psychiatric disorders in areas of unmet medical need. The FOA will support milestone-driven early stage trials in pediatric and adult populations. First in human (FIH) and Phase Ib studies of novel Agents must assess target engagement (brain exposure), pharmacological effects, safety, and tolerability to assess feasibility for Phase II/proof of concept (PoC) studies in psychiatric disorders. Phase II/PoC studies must evaluate the drugs impact on clinically relevant physiological systems (functional measures) and clinical indicators of effect. The FOA also supports FIH and early feasibility studies (EFS) of novel devices to evaluate target engagement, safety, tolerability, and efficacy. The overall objective is to facilitate rapid collection of data to "de-risk" novel mechanism of action investigational drugs, novel drugs for use in pediatric populations with psychiatric disorders, and devices or combination treatments in order to attract private funding for further clinical development as FDA-approved treatments. A key aspect of this FOA is the formation of collaborative partnerships between the biomedical researchers and biotechnology or industry researchers to facilitate psychiatric drug or device development.